Rutgers Cancer Institute of NJ — New Brunswick, New Jersey

Rutgers Cancer Institute of NJ is a clinical research site located in New Brunswick, New Jersey, United States 08903.

Crixeo Health Trust Score: 75/100 (FAIR). This profile has not yet been claimed by the site owner.

Rutgers Cancer Institute of NJ has participated in 8 clinical trials with 4 currently active.

Therapeutic areas: Endometrial Adenocarcinoma, Chronic Myelogenous Leukemia - Chronic Phase, Ovarian Cancer.

Sponsors: Acrivon Therapeutics, Novartis Pharmaceuticals, USWM CT, LLC.

Sponsor Feasibility Report

Trust Score: 75/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rutgers Cancer Institute of NJ?

Rutgers Cancer Institute of NJ has a Crixeo Trust Score of 75/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rutgers Cancer Institute of NJ conducted?

Rutgers Cancer Institute of NJ has 8 clinical trials on record, with 4 currently active. Their work covers Endometrial Adenocarcinoma, Chronic Myelogenous Leukemia - Chronic Phase, Ovarian Cancer.

Is Rutgers Cancer Institute of NJ accredited by Crixeo Health?

Yes — Rutgers Cancer Institute of NJ holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Rutgers Cancer Institute of NJ?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.